Memory Pharma says bipolar disorder drug fails trail
March 5 (Reuters) - Memory Pharmaceuticals Corp. (MEMY.O: Quote, Profile, Research, Stock Buzz) said its experimental drug for treating acute mania in bipolar disorder proved ineffective in a mid-stage trial.
However, the company will go ahead with its trials of the drug for use in Alzheimer's disease, it said in a statement.
(Reporting by Anant Vijay Kala in Bangalore)
((Editing by Anil Kumar; Reuters Messaging: anant.kala.reuters.com@reuters.net; within U.S. +1 646 223 8780; outside U.S. +91 80 4135 5800)) Keywords: MEMORY DRUG/
(C) Reuters 2007. All rights reserved. Republication or redistribution ofReuters content, including by caching, framing or similar means, is expresslyprohibited without the prior written consent of Reuters. Reuters and the Reuterssphere logo are registered trademarks and trademarks of the Reuters group ofcompanies around the world.nWNAS2926
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Cash injection
G7 vows to tackle global crisis